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affected by the rs225014 risk allele and joint type (P¼ 3.6 * 10-3 and P¼
4.2 * 10-2, respectively) Furthermore, we observed a single CpG dinu-
cleotide 2 kB upstream of the DIO2 promoter that displayed a signiﬁcant
positive correlation with expression of DIO2 (P ¼ 3.3 * 10-3). In addi-
tion, this CpG dinucleotide appeared signiﬁcantly hypermethylated in
OA cartilage, compared to matched preserved cartilage (P ¼ 1.6 * 10-4)
(Figure 1). Subsequent stratiﬁcation for rs225014 genotypes revealed an
enhanced relation between methylation and expression in carriers of
the rs225014 risk allele. Further stratiﬁcation for joint type did not
reveal any major differences. ChIP on multiple chondrocyte cell lines
identiﬁed a CTCF binding site directly on the location of the identiﬁed
CpG.
Conclusions: Compelling regulatory properties of a single CpG dinu-
cleotide 2 kB upstream of the DIO2 promoter seem responsible for the
observed up regulation of DIO2 expression in OA cartilage, independent
of rs225014 genotypes. However, expression of DIO2 is additionally
modulated by rs225014 genotypes. As a result expression of DIO2 in risk
allele carriers is more sensitive to changes in methylation, indicating an
additive effect, which in turn could be causal to OA susceptibility.
Figure 1. Overview of interrogated CpG dinucleotides in the DIO2 locus. The sixth CpG
dinucleotide from region D associates signiﬁcantly with DIO2 expression (P ¼ 0.0033)
and is differentially methylated between preserved and OA cartilage (P ¼ 1.6 * 10-4).
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GENETIC RISK FACTORS FOR KNEE OA DISPLAY GOOD PREDICTIVE
POWER IN A HIGH RISK GROUP OF OVERWEIGHT AND OBESE
FEMALES
J.B. van Meurs, J. Runhaar, M. Verbiest, S. Bierma-Zeinstra. Erasmus MC,
Rotterdam, Netherlands
Purpose: Over the last few years, several genetic markers have been
identiﬁed to be robustly associated with knee osteoarthritis (OA). These
genetic markers have been identiﬁed by gathering all cases and controls
available. In general, small effect sizes of these risk factors were found,
making OA genetic risk prediction difﬁcult. However, it is known that
the association of the genetic marker with the phenotype can be
context speciﬁc. It could be that in persons with or without major
environmental risk factors, different sets of genes are important. We
therefore set out to test predictive value of DNA variants previously
identiﬁed as being associated to knee OA, in a high risk group of over-
weight and obese, middle-aged women.
Methods:
Study Sample: This study was performed within the PRevention of knee
Osteoarthritis in Overweight Females (PROOF) study. A total of 407
women met the inclusion criteria (BMI  27, no clinical knee OA (ACR
criteria), no contraindications to MRI, no rheumatic diseases), were
invited for baseline measurements. Pre-speciﬁed primary outcome was
incidence of knee OA, deﬁned by incidence of either K&L 2, joint space
narrowing of  1.0 mm or incident clinical knee OA (ACR criteria). After
2.5 years of follow-up, forty-three women (11%) were lost to follow-up
and for a further 72 women no DNA was available.
DNA-variants: We studied DNA variants that have been reported as
being associated with knee OA at genome-wide signiﬁcance level
(P<5x10-8) in women. These included variants in or near: GDF5
(rs143383), GNL3 (rs11177) and DUS4L (also referred to as the Chr 7
locus, rs4730250) and MCF2L (rs11842874). The assay for the MCF2L
variant failed due to technical problems. We subsequently computed
a genetic risk score for the 3 variants that were genotyped successfully,
where the number of carried risk alleles where added per person.
Association between the genetic markers, the genetic risk score andincident knee OAwas tested bymultivariate logistic regression analysis,
adjusting for age and BMI.
Results: In total 92 (31%) women developed OA during the 2.5 year
follow-up time. When the risk for the separate DNA variants were
tested, for all three variants we found increased risk for incident knee
OA with the previously identiﬁed risk allele (OR(95% CI): GDF5: 1.30
(0.91-1.85); GNL3: 1.23(0.86-1.78); Chr7: 1.75(1.10-2.77)). All these risks
were at least twice as large as compared to those previously reported in
large meta-analysis. However, only the odds ratio for the chr 7 locus
reached nominally signiﬁcance (p¼0.018). The genetic risk score, which
was composed of the three SNPs under study, was signiﬁcantly asso-
ciated with incident knee OA (p¼0.007). With each additional risk
allele, the women had 38% more chance for incident knee OA. Whenwe
stratiﬁed the women into 3 groups according to their genetic risk score,
we observed that womenwith 4 or 5 genetic risk alleles had almost 3.5
times higher risk for incident knee OA compared to women that had
0 or 1 risk allele (OR 3.45 (95%CI 1.41-8.47), p¼0.007).
Conclusions: The previously identiﬁed genetic risk markers for knee
OA, were signiﬁcantly associated with incident knee OA in this high risk
group of overweight and obese women. The effect sizes of the studies
DNA variants were larger than those reported previously. These results
indicate that genetic prediction of OA can be dependent on the presence
of other strong clinical risk factors38
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Purpose: The Osteoarthritis Initiative (OAI) is a multicentre study
focused on identifying and evaluating risk factors of knee osteoarthritis
(OA). Previous studies carried out by our group showed the role of the
mitochondrial DNA (mtDNA) haplogroups on the prevalence and
progression of OA. The aim of this study is to replicate our previous
ﬁndings about the inﬂuence of the mtDNA haplogroups on OA
progression in the well characterized cohort of the OAI.
Methods: Data for these analyses are from the OAI public use data
set(s), and assigned the mtDNA haplogroups in 891 Caucasian samples
of the progression subcohort.
We analyzed the inﬂuence of mtDNA haplogroups on OA progression
attending to KL grade, joint space narrow (JSN), presence of osteophytes
and subchondral sclerosis in media tibial compartment, between
baseline and visit 6 (48 months). The progression criteria for KL grade
consisted in an increase of at least one (KL or OARSI) grade to any visit
and any knee; for JSN we considered progression if an increase in score
by a grade above or equal to 0.5 of the OARSI scale to any visit and any
knee occurred. Additionally we also analyzed the inﬂuence of these
mitochondrial polymorphisms on quantitative measurements of carti-
lage morphology from magnetic resonance imaging (MRI) scans: mean
cartilage thickness and volume of cartilage in medial tibia. Appropriate
statistical analyses adjusting by gender, age and body mass index (BMI)
at baseline were carried out using SPSS software (v.19).
Results: Carriers of the mtDNA haplogroup T are at lower risk for KL
grade progression (27.1 % progressors) than carriers of the most
common mtDNA haplogroup H (46.9% progressors) (OR¼0.442;
CI¼0.233-0.835; p¼0.012). As expected, carriers of the haplogroup T are
also better progressors, attending to osteophytes (35.2% progressors)
and subchondral sclerosis (30.2% progressors) in tibia medial
compartment, than carriers of the haplogroup H (53.4% progressors and
45.8% progressors respectively) (OR¼0.481; CI¼0.258-0.897; p ¼ 0.021
and OR¼0.525; CI¼0.275-1.004; p ¼ 0.05 respectively). Regarding to
JSN, carriers of the haplogroup T also showed a better progression
(23.3% progressors) than carriers of the haplogroup H (36.9% pro-
gressors) (OR¼0.510; CI¼0.261-0.995; p ¼ 0.048).
The analyses of quantitative measurements of cartilage morphology
revealed that carriers of the haplogroup T showed a higher mean
cartilage thickness in medial tibia (1.88 mm  0.28) than carriers of the
haplogroup H (1.74 mm 0.27) (borderline p¼ 0.077), as well as higher
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2019.59  577.78 mm3 for haplogroup H) (p ¼ 0.009).
Conclusions: This work strength the hypothesis that mitochondrial
genome is a key factor in the progression of the OA disease. The early
identiﬁcation and classiﬁcation of patients with haplogroup T and the
most common haplogroup H would permit to carry out a more
personalized follow-up of the disease.39
SMAD3 GENE IS ASSOCIATED WITH GENERALIZED OSTEOARTHRITIS
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Background: Osteoarthritis (OA), the most common form of arthritis in
the elderly, causes pain, stiffness, a limited range of motion, joint
deformity and disability, and imposes a high economic burden on
society. OA is a multifactorial disease with both genetic and environ-
mental factors involved. A newly-described syndrome called Aneu-
rysm-Osteoarthritis Syndrome (AOS) was recently reported. AOS
presents with early onset OA in multiple joints, together with aneu-
rysms in the major arteries, and is associated with eight rare mutations
in the SMAD3 gene. Because of the similarity with AOS, we hypothe-
sized that SMAD3 is also associated with idiopathic generalized OA
(GOA) and tested our hypothesis in a large OA cohort.
Methods: Study participants were derived from TwinsUK cohort.
Radiographic OA in the hands, knees and hips were assessed using the
Kellgren-Lawrence (K/L) scoring system. Joints with a K&L score2
were deﬁned as affected. GOA patients were deﬁned as those with at
least two joints (hand, knee, or hip) affected. Genotypes on all 41 SNPs
within SMAD3 (genotyped with the Illumina HapMap 610K chip) were
retrieved from the TwinsUK database. A robust logistic regression
model was used to test the association between GOA and SMAD3 with
adjustment for age, BMI, and relatedness.
Results: A total of 204 patients with GOA and 477 individuals without
radiographic OAwere included in the ﬁnal analysis. All 41 SNPs were in
HWE. We found that rs6494629 is strongly associated with GOA, with
an OR of 1.89 (95% CI 1.2-2.8, p¼0.002). Four additional SNPs, all within
100 kb of rs6494629 in the ﬁrst intron, were also associated with GOA
(all p<0.05). In addition, we found rs893473 to be associated with knee
OA (OR¼1.8, P¼0.02, CI¼ 1.09-3.09); rs12913547 (OR¼ 1.5, P¼ 0.025,
CI¼ 1.05-2.35) and rs4601989 (OR¼ 1.4, P¼ 0.041, CI¼ 1.01-2.2) with hip
OA; and rs6494629 (OR¼ 1.44, p¼0.025, CI¼ 1.04-1.9), rs3825977 (OR¼
0.59, p¼ 0.026, CI¼ 0.3-0.9), rs16950687 (OR¼ 0.6, p¼0.035, CI¼ 0.4-
0.9) to be associated with hand OA. The associations with individual
joint OA are weaker compared with GOA.
Conclusion: We demonstrated that variations in the SMAD3 gene are
strongly associated with GOA. Further studies are required to reveal the
potential mechanism for the association.40
STRONTIUM RANELATE EFFECT ON KNEE OSTEOARTHRITIS
PROGRESSION
S. Zaim y, A. Guermazi z,x, F. Roemer z, A. Beaulieu k, S. Hall {, L.
Alekseeva #, J. Grifka yy, L. Roorda zz, G. Verbruggen xx, R. Wittoek xx, C.
Peterfy kk, C. Cooper {{, J.-Y. Reginster ##, H. Genant yyy. y SYNARC,
Newark, CA, USA; zRadiology, Boston Univ. Sch. of Med., Boston, MA,
USA; x Synarc, San Francisco, CA, USA; kCtr. de Rhumatologie St-Louis,
Québec, QC, Canada; { Emeritius Res., Malvern East, Australia; # Inst. of
Rheumatology of RAMS, Moscow, Russian Federation; yyAsklepios
Klinikum Bad Abbach, Bad Abbach, Germany; zzAmsterdam
Rehabilitation Res. Ctr. Reade, Amsterdam, Netherlands; xxGhent Univ.
Hosp., Ghent, Belgium; kk Spire Sci., San Francisco, CA, USA;
{{ Southampton Gen. Hosp., MRC Lifecourse Epidemiology Unit,
Southampton, United Kingdom; ##Dept. of Publ. Hlth. Epidemiology and
Hlth. Economics of the Univ. of Liège, Liège, Belgium; yyyRadiology, Med.
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San Francisco, CA, USAPurpose: In the SEKOIA study, strontium ranelate (SrRan) has demon-
strated radiographic structure-modifying activity, by lowering joint
space narrowing progression compared to a placebo group. The aim of
this analysis was to evaluate the effect of SrRan on knee cartilage and
bone in a subset of patients that underwent MRI.
Method: SEKOIA is a large international, randomised, placebo-
controlled phase III, 3-year study. Included patients were men and
women over 50 years of age, with symptomatic primarymedial knee OA
(at least 40 on a 100-mm visual analog scale on most days of the
previous month, a Kellgren and Lawrence [KL] grade 2 or 3, and joint
space width [JSW] of 2.5-5 mm). MRI was performed at inclusion and
then annually in a subset of patients from 36 centers. Images were
centrally read (Synarc Inc, Hamburg, Germany) and the joint tissue
pathology (cartilage morphology, bone edema, subchondral cysts, bone
attrition, osteophytes, meniscal damage, synovial effusion.) was
evaluated semiquantitatively using the WORMS method. SrRan 1g and
SrRan 2g treatment groups were compared to placebo for the change
from baseline to the last value, using a general linear regression model
adjusted with gender, center and baseline values as covariates. Patients
who had a worsening of their score of at least 1 were compared among
groups using a chi2 test.
Results: MRI ITT included 364 patients. At baseline, the mean age was
627years, BMI was 29.94.9 kg/m2, and JSW was 3.50.8 mm. 65%
were KL grade 2 and 67%were female. Therewere no differences among
groups at baseline. Over 3 years, progression in WORMS score occurred
in less than 45% of the patients for cartilage morphology and less than
20% of the patients for other joint features. There were no differences
between treatment groups in mean changes for any parameters. The
number of patients with a deterioration of the cartilage morphology
was signiﬁcantly lower in the SrRan 2g group than in the placebo group
in the lateral compartment (3.4%, 4 patients vs. 15.7%, 19 patients;
p¼0.001). No difference was observed in the medial compartment (25%
vs 27% in the SrRan 2g and placebo groups, respectively).. For bone
features, fewer patients had aworsening of their osteophyte score in the
medial compartment in the SrRan 2g group than in the placebo
group(12.0%, 14 patients vs. 23.0%, 28 patients; p¼0.026), a similar
trend was observed in the lateral compartment (p¼0.085). No statisti-
cally signiﬁcant differences were observed for the SrRan 1g group
compared to placebo (14 patients (11.4%, p¼0.324 for lateral cartilage
morphology, and 23 patients (18.7), p¼0.259) for medial osteophytes).
Despite the small number of patients concerned, numerically fewer
patients had a worsening of bone attrition score in the SrRan 2g group
(2.6% vs. 6.6%) in the medial compartment. Very few meniscal extru-
sions were observed (less than 6 patients per group) over 3 years.
Conclusions: Within the limits of the small number of patients who
have a detectable change, strontium ranelate 2g/day reduces cartilage
degradation and progression of osteophytes, and tends to decrease
bone attrition in patients with knee osteoarthritis.41
ROLE OF VITAMIN D IN OSTEOARTHRITIS KNEE: A SIX MONTH
DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROL TRIAL
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Purpose: There is a putative role of vitamin D in osteoarthritis (OA)
based on animal, epidemiological and human clinical studies. Short
term clinical studies suggest beneﬁcial inﬂuence of vitamin D on local
changes in the bone which probably accounts for diminished pain
experienced in knee OA (KOA). Inadequate sunlight exposure and lower
serum levels of 25(OH)D appears to be associated with an increased risk
for progression of OA knee. Some chronic analgesic users with OA knee
were more likely to be in lower categories of 25(OH) D compared to
women with asymptomatic OA. On the basis of above background this
study was planned to assess the effect of vitamin D on the progression
of disease.
Methods: A six month, double blind, randomized and placebo
controlled trial of vitamin D, in vitamin D insufﬁcient OA knee subjects
(serum 25(OH)D levels <50 nmol/L) was conducted. 150 subjects of
primary OA knee, diagnosed by ACR guidelines, were subjected to
personal interview to determine their vitamin D intake (by 3 day die-
tary recall and food frequency table) and the daily sunlight exposure in
hours. Serum levels of calcium, phosphorus, alkaline phosphatase and
